PubMed Health⌕ Search

Biomedical subjects

V M Moiseenko

Publications and source records attributed to V M Moiseenko.

At least 37 records · Page 2Linked to original sources
PubMed1999

[Effectiveness of current chemotherapy in metastatic breast cancer resistant to anthracycline antibiotics].

The efficacy of different antitumor therapies was evaluated in a study involving 53 patients with metastatic breast cancer resistant to anthracyclin antibiotics. Complete and partial regression of tumor was recorded following combined administration of vinorelbin and doxorubicin (27.3%) and taxanes (21.3%). Median therapeutic benefit duration was 22 and 28 weeks, respectively. Response frequency for mitomicin C + mitoxantron + methotrexate regimen was 11.1%. However, no objective therapeutic effects were observed in patients on ifosfamide + mitoxantron and regular 5-fluorouracil infusins.

Adult↗
PubMed1997

[Subchondral endoprosthesis in combined treatment of patients with primary and metastatic tumors of long tubular bones].

The report deals with the results of organ-saving surgery for subchondral endoprosthesis carried out in 31 patients with primary tumors and pathological fracture of bones caused by metastasis. An original procedure using the anatomo-physiological peculiarities of cartilage permits to preserve the physiological status of the joint. Lysis of tumor cells in subchondral bone is caused by methyl acrylate used as bone cement. Administration of adaptogen-immunomodulators promotes postoperative healing processes and lowers the risk of infection-related complications.

Adolescent↗
PubMed1996

[Effectiveness of adjuvant hormone therapy in breast cancer].

A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy (tamoxifen, diethylstilbestrol, orimethen amino glutethymide) in breast cancer patients. Tamoxifen was studied in 176 patients with T1-2N0M0 tumors. Five-year recurrence-free survival was registered in 85.2% of menopausal patients treated with tamoxifen versus 71.1% in control (P < 0.05). Five-year recurrence-free survival in menopausal females with breast tumors, stage IIb, was 71.1% among those treated with diethylstilbestrol and as low as 57.4% in the tamoxifen group (P < 0.05). Untoward side-effect incidence was much higher in the diethylstilbestrol group (30.4%) as compared with tamoxifen (3.5%). No significant difference was found for the relationship between orimethen and tamoxifen treatment with respect to 5-year survival and recurrence-free survival.

Aminoglutethimide↗
PubMed1996

[Preliminary results of the Russia (St.Petersburg)/WHO program for the evaluation of the effectiveness of breast self-examination].

Although an absolute difference of 10% (65,4 vs. 54,9%) in 5- and 9-year survival in breast cancer patients was recorded between the self-examination and control groups a large-scale randomized population-controlled study of 122,471 females has failed to provide significant differences (Log-rank - 0,774, p > 0.05). No significant decrease in mortality was observed in the self-examination group as compared with the untrained controls. As a result of providing more information to the population on risk factors. twice as many of the trained females consulted oncologists. Also, the number of early detection of breast tumor (T1-2NOMO) in both groups was 1,5-2,5 times that recorded elsewhere. Since 3,55 per 1,000 patients with breast tumors per year, aged 50-59, died of cardio-vascular disease, i.e. 3,1 times the expected 1,16 per 1,000, more attention should be focused on timely diagnosis and treatment of concomitant cardio-vascular pathology.

Adult↗
PubMed1996

[Hormone therapy of advanced renal cancer with high-dose toremifene (Fareston)].

Toremifene (Fareston)-a novel antiestrogenic drug with a triphenylethylene structure-has been effective in the treatment of postmenopausal breast cancer patients. It is safely administered even in high doses up to 300 mg/day. The purpose of the study was to investigate the effect and tolerability of high dose toremifene in the treatment of patients with advanced renal cell carcinoma (RCC). Thirty six patients started the treatment with toremifene 300 mg/day. There were 26 males and 10 females. Mean age was 56.0 years, range 35-75 years. Nineteen patients were nephrectomized. One patient was not evaluable for response because of too short treatment time. The response rate was 17.1%, including 1 CR (2.9%) lasting for 121 + weeks and 5 PR (14.3%) with the mean duration of 39.8 + weeks. Ten cases of NC (28.6%) had the mean duration of 23.7 weeks. There were no significant differences in response rate when patients with lung metastases only were compared to patients with metastases of other sites with or without lung metastases. Total pain control was achieved in 45% and partial control in 20% of those patients who had pains in the beginning of the treatment. Ten patients (27.8%) had adverse reactions which led to discontinuation of the treatment in one case. It can be concluded that high-dose toremifene is an effective and safe means of palliative treatment in advanced RCC.

Adult↗
PubMed1996

[Postoperative hormone therapy of breast cancer (analysis of overall survival)].

A third series of randomized evaluation of postoperative (adjuvant) hormone therapy (tamoxifen, sinestrol and orimeten) was carried out in breast cancer patients. The study group involved 1.332 reproductive and postmenopausal females with stage I-III tumors. The investigation established quite a range of 10-year survival evidence versus stage and reproductive status; however, no significant differences were recorded in either of the groups. Untoward side-effects were more frequent when treating with diethyl-stilbestrol (over 30%) than with tamoxifen (3.5%). No significant differences were registered in five-year total and recurrence-free survival in the treatment with orimeten or tamoxifen.

Adult↗
PubMed1994

[Does breast cancer grow slower in elderly patients?].

Retrospective analysis of repeated mammograms (2-4) was undertaken to establish actual tumor doubling time (DT) in 109 patients with breast tumors. Potential DT was determined on the basis of the proliferative activity of tumor cells evaluation using thymidine label technique. A direct correlation between age and morbidity was found for both fast--(DT < 35 days) and slow-growing (DT > or = 110 days) tumors.

Adult↗
PubMed1992

[The risk factors for breast cancer (a prospective controlled study)].

Preliminary results of a prospective study of known risk factors for breast cancer are discussed in the paper. The study included 42,785 females aged 40-64 years who were followed for 2-5 years (mean--3.1 years). Within this period, 146 cases of breast cancer were registered. A significant (p < 0.05) increase in the relative risk (RR) of breast cancer was established for females aged over 50 (50-59 years--RR-1.4; 95% CI--1.0-2.0 and 60-64 years-RR--2.4; 95% CI 1.6-3.7), overweight patients (RR--1.5; 95% CI--1.1-2.1), subjects who developed menopause after the age of 50 (RR--1.6; 95% CI--1.1-2.2) and those with a ten-year or longer history of liver or bile ducts pathologies (RR--1.7; 95% CI--1.1-2.7). The role of certain factors differed significantly in different age groups. At the age of 40-49 years, the RR of breast cancer rose significantly for overweight subjects (RR--2.0; 95% CI--1.2-3.4) and those with liver pathologies (RR--2.5; 95% CI--1.3-4.6), at the age of 50-59-for subjects with late (after the age of 50) menopause (RR--2.0; 95% CI--1.2-3.4) and at the age of 60-64 years-for nulligravidae (RR--2.8; 95% CI--1.1-6.8).

Adult↗
PubMed1992

[Chromosomal restructurings and the distribution of chromosome fragile sites in the peripheral blood lymphocytes in a breast cancer patient after cytostatic therapy].

Cytogenetic analysis was performed repeatedly on a breast cancer patient since the beginning of the antitumor treatment. Double minute chromosomes (DMS, 2-10 per cell) were found in less than 2% of peripheral blood lymphocytes besides other chromosomal abnormalities after radiation therapy and 8 months after chemotherapy. The level of structural chromosomal aberrations two years after the therapeutic treatment was 0.13-0.14 aberrations per cell, but DMS were not observed. Estimation of the fragile site (FS) frequency and distribution at this time revealed a significant expression of the common FS FRAGF (9q1.2) after the treatment of blood culture with 5-bromo-2-deoxyuridine at dose levels of 7 and 50 g/l and enhanced fragility in chromosome band 1p35-36.1 (FRA1A) in folate-deprived conditions. Rare FS were not found. The presented data are discussed.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

[The morphological characteristics of primary breast cancers with different growth rates].

Morphologic peculiarities of primary breast cancer versus growth rate were studied in 46 cases. Growth rate (actual doubling time) was established by mammography carried out at certain time intervals. Morphologic investigation included assessment of tumor histology, degree of invasion, growth pattern, presence of pathologic mitoses, degree of blood vessel invasion, degree of necrosis, presence of microcalcinates, type of desmoplastic reaction, peculiarities of cell infiltration, background and regional lymph node reaction, and grade of malignancy. None of the above parameters appeared to correlate with tumor growth rate. It is concluded that standard morphologic examination of tumor be supplemented with assessment of its proliferative activity.

Adult↗